Business

The funding includes $4.5 billion for the firm's core VC funds, $1.5 billion for its Creation strategy and $2 billion for separately managed accounts.

The round was led by Andreessen Horowitz, which has announced two other significant digital health investments within the past two weeks.

The message-based platform allows patients to get answers to complex medical questions, receive second opinions, seek urgent care and obtain assistance with end-of-life decisions.

The New York-based company will use the investment to grow its partnerships and coverage among payers and move into Medicare populations in 2025.

The company helps FQHCs, STD and Ryan White clinics develop, operate and grow in-house pharmacy programs focused on HIV and Hepatitis C patient populations.

The company will be subject to a 12-month follow-up review period to assure that it does not fall below NYSE standards.

The company will use the funds to accelerate its product expansion on a global scale.

The Series A funding announcement comes less than a month after the company announced integration capabilities with AWS, Google Cloud, Databricks and Snowflake.

The modernized, outcomes-focused AMAM is meant to help health systems keep pace with the rapid evolution of analytics technologies and artificial intelligence and "support equitable, data-driven decision-making at scale."  

The company will use the funds to expand its partnerships with Athena, Oracle Cerner, Epic and MEDITECH, and to enhance its offerings, Suki Assistant and Suki Platform.